Amazon Bio Discovery cut MSK antibody design from a year to weeks, AWS says

AWS launches Amazon Bio Discovery, a new AI application pairing biological foundation models with integrated lab testing to accelerate drug development. Amazon Web Services today launched Amazon Bio Discovery, an application that routes AI-designed antibody candidates directly to DNA Synthesis firm Twist Bioscience and the techbio Ginkgo Bioworks for synthesis and testing, with results flowing back into the same interface that generated them. AWS launched Amazon Bio Discovery with Bayer, the Broad Institute, Memorial Sloan Kettering and Voyager Therapeutics among its early adopters. The application pairs that integrated wet-lab handoff with a catalog of biological foundation models (bioFMs), large AI…

Source: Drug Discovery & Development